{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003268","form_type":"8-K","ticker":"DSS","cik":"0000771999","company_name":"DSS, INC.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.895927+00:00","generated_at":"2026-06-06T20:51:08.937364+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030","bullets":["Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.","Maturity extended to September 30, 2030; interest-only payments through Jan 2026, then monthly $126,380.80.","Interest rate set at WSJ Prime + 0.50% (initial 9.00%); secured by blanket first lien on all Impact assets including patents.","DSS is the lender and majority shareholder of Impact BioMedical, indicating continued related-party support."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003268","json":"https://secwatch.observer/filing/0001493152-24-003268.json","markdown":"https://secwatch.observer/filing/0001493152-24-003268.md","text":"https://secwatch.observer/filing/0001493152-24-003268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/0001493152-24-003268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:51:08.937364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7084a6ca1b9897ba112a18388eff1b637454f1b","claim":"DSS, INC. amended Amendment with Impact BioMedical, Inc. valued at $859,328.60 (effective 2024-01-18).","evidence_excerpt":"Effective January 18, 2024, DSS, Inc. (the “Company”) and Impact BioMedical, Inc., a Nevada corporation (“Impact”) entered into an amendment to the revolving promissory note dated March 1, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/0001493152-24-003268-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Impact BioMedical, Inc."},{"label":"Value","value":"$859,328.60"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}